News | October 09, 2022
BioMarin simplifies organizational structure to increase efficiency
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
Collaboration supports multiple discovery efforts, including vaccines
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Subscribe To Our Newsletter & Stay Updated
